Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 6/20 | 0.72 |
| ▸ | ESR1 | P03372 | 5/20 | 0.72 |
| ▸ | PHGDH | O43175 | 1/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.49 |
| ▸ | ABHD6 | Q9BV23 | 3/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | ACACB | O00763 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29963966 | 1.00 | ESR2 (0.72) | ESR2ESR1PHGDHNOTUMABHD6 | |
| SCHEMBL3865684 | 0.94 | ESR1 (0.72) | ESR2ESR1PHGDHNOTUMABHD6 | |
| SCHEMBL27176737 | 0.91 | ESR1 (0.58) | ESR2ESR1PHGDHNOTUMABHD6 | |
| SCHEMBL7641635 | 0.89 | ESR2 (0.68) | ESR2ESR1PHGDHNOTUMABHD6 | |
| SCHEMBL2930510 | 0.87 | ESR2 (0.54) | ESR2ESR1PHGDHNOTUMABHD6 | |
| SCHEMBL16759871 | 0.85 | ESR2 (0.53) | ESR2ESR1PHGDHNOTUMABHD6 | |
| SCHEMBL8176145 | 0.84 | ESR2 (1.00) | ESR2ESR1ABHD6HDAC6HDAC8 | |
| SCHEMBL14101113 | 0.83 | ESR1 (0.68) | ESR2ESR1ABHD6HDAC6HDAC8 | |
| SCHEMBL18701688 | 0.83 | ESR1 (0.57) | ESR2ESR1NOTUMHDAC6HDAC8 | |
| SCHEMBL25206226 | 0.82 | ESR2 (0.76) | ESR2ESR1ABHD6HDAC6HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112094229-B | Synthesis method of 6- (trifluoromethyl) isoquinoline-5-alcohol | 苏州康润医药有限公司 | 2022-11-22 | — | — | CN | claimed |
| CN-112094229-A | Synthesis method of 6- (trifluoromethyl) isoquinoline-5-alcohol | 苏州康润医药有限公司 | 2020-12-18 | — | — | CN | claimed |
| CN-112094229-B | Synthesis method of 6- (trifluoromethyl) isoquinoline-5-alcohol | 苏州康润医药有限公司 | 2022-11-22 | — | — | CN | disclosed |
| CN-112094229-A | Synthesis method of 6- (trifluoromethyl) isoquinoline-5-alcohol | 苏州康润医药有限公司 | 2020-12-18 | — | — | CN | disclosed |
| WO-2019044940-A1 | CYCLIC AMINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | 東レ株式会社 | 2019-03-07 | — | — | WO | disclosed |
| EP-1844045-B1 | PHENYL METHANONE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER 1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-11-04 | — | — | EP | disclosed |
| EP-1844045-B1 | PHENYL METHANONE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER 1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-11-04 | — | — | EP | disclosed |
| US-7442710-B2 | Substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442710-B2 | Substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442710-B2 | Substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1844045-A1 | PHENYL METHANONE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER 1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-10-17 | — | — | EP | disclosed |
| US-7166614-B2 | Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-7166614-B2 | Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2007-01-23 | — | — | US | disclosed |
| WO-2006079467-A1 | PHENYL METHANONE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER 1 INHIBITORS | F. HOFMANN-LA ROCHE AG (CH) | 2006-08-03 | — | — | WO | disclosed |
| US-20060167023-A1 | Substituted phenyl methanones | HOFFMANN-LA ROCHE INC. | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167023-A1 | Substituted phenyl methanones | SLC6A7, SLC1A1, SLC26A3 | ESR2 1325/4885ESR1 864/4885PHGDH 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.